Squarepoint
PRCT icon

Squarepoint’s Procept Biorobotics PRCT Stock Holding History

Squarepoint’s Portfolio PRCT Stock Details PRCT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q1 		– Sell
-12,100
Closed -$974K – 5230
2024
Q4 		$974K Buy
12,100
+1,500
+14% +$128K ﹤0.01% 3090
2024
Q3 		$849K Buy
10,600
+6,200
+141% +$440K ﹤0.01% 2719
2024
Q2 		$269K Sell
4,400
-28,000
-86% -$1.67M ﹤0.01% 3494
2024
Q1 		$1.6M Buy
+32,400
New +$1.54M ﹤0.01% 2246

Other funds holding PRCT

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $145B AUM 22.78% 1-Year Est. Return
BNP Paribas Asset Management
BNP Paribas Asset Management Paris, France $86.1B AUM 29.11% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
CC
Chicago Capital Chicago, Illinois $3.71B AUM 19.51% 1-Year Est. Return
PM
Prosight Management Dallas, Texas $610M AUM 40.86% 1-Year Est. Return
Mackenzie Financial
Mackenzie Financial Toronto Ontario, Ontario, Canada $83.3B AUM 31.19% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Squarepoint's PRCT Position: Q1 2026 in Review

Squarepoint sold out of Procept Biorobotics (PRCT) in Q1 2026, closing a stake of 191,581 shares — an estimated $6.03M sold.

Squarepoint first reported a position in PRCT in Q3 2021 and held it in 12 quarters. The position peaked at $12.9M in Q1 2025. 256 funds tracked by Wall St. Rank hold PRCT as of Q1 2026.

  • Squarepoint reported no remaining Procept Biorobotics position as of Q1 2026 after selling out during the quarter.
  • Squarepoint sold 191,581 Procept Biorobotics shares in Q1 2026, an estimated $6.03M.
  • Squarepoint first reported a position in Procept Biorobotics in Q3 2021 and held it in 12 quarters.
  • Squarepoint's Procept Biorobotics position peaked at $12.9M in Q1 2025.
  • 256 funds tracked by Wall St. Rank held Procept Biorobotics as of Q1 2026.

Based on Squarepoint's 13F filing for Q1 2026, filed 15 May 2026.